Loading…
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $13.6B | $2.6B | $747M | $1.3B | -114.7% | 6.5% | -20.2% |
| 2024 | $12.8B | $2.7B | $936M | $1.5B | 773.1% | 5.6% | 35.4% |
| 2023 | $12.1B | $2.3B | $692M | $1.5B | 65.5% | 4.6% | 23.4% |
| 2022 | $11.6B | $2.1B | $560M | $961M | 78.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 11,609.89 | 12,140.15 | 12,815.55 | 13,643.07 |
| Cost Of Revenue | - | 8,209.55 | 8,319.72 | 8,598.52 | 9,243.48 |
| Gross Profit | - | 3,400.34 | 3,820.43 | 4,217.03 | 4,399.59 |
| Operating Expense | - | 2,087.80 | 2,219.43 | 2,262.20 | 2,388.98 |
| Operating Income | - | 1,312.54 | 1,601 | 1,954.83 | 2,010.62 |
| EBITDA | - | 2,055.90 | 2,321.09 | 2,724.72 | 2,642.10 |
| EBIT | - | 1,323.30 | 1,575.64 | 2,000.86 | 1,926.75 |
| Pretax Income | - | 966.28 | 1,177.09 | 1,530.39 | 1,346.82 |
| Tax Provision | - | 198.09 | 220.12 | 279.66 | 293.11 |
| Net Income | - | 560.40 | 691.54 | 936.34 | 746.80 |
| Net Income Common Stockholders | - | 560.40 | 691.54 | 936.34 | 746.80 |
| Total Expenses | - | 10,297.35 | 10,539.14 | 10,860.72 | 11,632.45 |
| Interest Expense | - | 357.02 | 398.55 | 470.47 | 579.93 |
| Selling General And Administration | - | 1,355.20 | 1,473.98 | 1,538.34 | 1,673.63 |
| Normalized EBITDA | - | 2,055.90 | 2,355.13 | 2,635.07 | 2,656.28 |
| Normalized Income | - | 546.95 | 717.31 | 863.07 | 732.90 |
| Market Cap | 10,013.65 | 10,013.65 | 10,013.65 | 10,013.65 | 10,013.65 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| DaVita Inc.this co. | DVA | $11.3B | 13.41↓ discount | -15.38 | -114.7% | 8.41 |
| STERIS plc | STE | $21.8B | 35.42 | 3.30 | 9.3% | 17.52 |
| Incyte Corporation | INCY | $18.5B | 14.64 | 3.65 | 24.9% | 8.96 |
| Waters Corporation | WAT | $18.4B | 47.33 | 11.88 | 25.1% | 30.39 |
| Zimmer Biomet Holdings, Inc. | ZBH | $18.1B | 25.05 | 1.39 |
| - |
| - |
| - |
| - |
| 5.6% |
| 11.09 |
| Align Technology, Inc. | ALGN | $13.7B | 33.09 | 3.35 | 10.1% | 15.31 |
| The Cooper Companies, Inc. | COO | $12.6B | 33.53 | 1.53 | 4.6% | 14.33 |
| Solventum Corporation | SOLV | $11.9B | 7.64 | 2.35 | 30.8% | 6.29 |
| Universal Health Services, Inc. | UHS | $11.1B | 7.15 | 1.46 | 20.5% | 5.71 |
| Peer Median | - | 29.07 | 2.83 | 15.3% | 12.71 | |